UNSPSC 51372122: Hydrocodone bitartrate

This classification denotes an opioid receptor agonist and antitussive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NO70W886KK. European Medicines Agency schedules Hydrocodone bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02559MIG. Hydrocodone bitartrate generally arises in the molecular formula 2C18H21NO3.2C4H6O6.5H2O. The term 'hydrocodone bitartrate' is a European Pharmacopoeia designation.

UNSPSC 51372122 Hydrocodone bitartrate is a Commodity code that in practice spans state and local procurement of controlled pharmaceutical products, including opioid-based medications and harm-reduction supplies such as naloxone. Recent solicitations under this code show state and local health agencies purchasing pharmaceutical inventory to support community health programs, emergency response capabilities, and medication-assisted treatment initiatives. State health departments, county health authorities, and cooperative purchasing alliances are the primary issuing bodies; these agencies procure both branded and generic pharmaceuticals through competitive bidding, often requiring vendors to maintain compliance with FDA manufacturing standards, the Drug Supply Chain Security Act, and state pharmacy licensing requirements. Solicitations typically mandate delivery to designated health facilities, compliance with insurance and E-Verify requirements, and adherence to federal environmental and labor standards when federal funding is involved.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2026, response deadline (note: the due date in the source shows July 26, 2023, which appears to be a data error; the posted date is June 30, 2026). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program that would bypass traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities with a response deadline of March 26, 2026, and an effective date of July 1, 2026. MMCAP requires vendors to work with three authorized wholesalers and submit pricing in multiple formats; the contract includes a 3 percent administrative fee and performance penalties for late reporting or missed onboarding timelines. These solicitations indicate active state-level demand for pharmaceutical supply chain management and competitive pricing strategies among health authorities in the Southeast, South-Central, and Upper Midwest regions.